WO2023078273 - SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE
National phase entry:
Publication Number
WO/2023/078273
Publication Date
11.05.2023
International Application No.
PCT/CN2022/129122
International Filing Date
02.11.2022
Title **
[English]
SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE
[French]
CONJUGAISON SPÉCIFIQUE POUR UN CONJUGUÉ ANTICORPS-MÉDICAMENT
Applicants **
HANGZHOU DAC BIOTECH CO., LTD.
Building 12
No. 260 Sixth Street
ZhengTaiZhongZi Sci&Tech Park, HEDA
Hangzhou, Zhejiang 310018, CN
Inventors
ZHAO, Robert
1st
7 Loring Road
Lexington, MA 310018, US
YANG, Qingliang
4th Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
YE, Hangbo
4th Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
JIA, Junxiang
3rd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
ZHANG, Lingli
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
HUANG, Yuanyuan
4th Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
LI, Wenjun
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
WANG, Juan
1st Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
GUO, Huihui
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 31008, CN
YE, Zhicang
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
ZHAO, Linyao
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
BAI, Lu
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
LIU, Xiaolei
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
Priority Data
PCT/CN2022/123901
08.10.2022
CN
PCT/CN2021/128453
03.11.2021
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 10832 | |
| EPO | Filing, Examination | 23733 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 7510 |
Total: 43272 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein is a process for preparing a homogeneous conjugate of an antibody or antibody-like protein via linkage of cysteine sites between heavy-light chains in the IgG antibody or antibody-like protein. Provided herein also are methods of making the conjugates in a specific manner comprising either generation of specific thiols of an antibody or antibody-like protein agent, followed by reaction with drug/linker complexes, or generation of specific thiols of an antibody or antibody-like protein agent and conjugation of a synthetic linker-drug assembly with the thiols simultaneously in one pot reaction, to provide conjugates with over 75%, in most cases more than 80%of payloads linked at the specific cysteine sites between heavy-light chains of the IgG antibody or antibody-like protein. It also relates to methods of using the homogeneous conjugate in targeted prophylaxis or treatment of cancer, infection and immunological disorders.[French]
L'invention concerne un procédé de préparation d'un conjugué homogène d'un anticorps ou d'une protéine de type anticorps par liaison de sites de cystéine entre des chaînes légères-lourdes dans l'anticorps IgG ou la protéine de type anticorps. La présente invention concerne également des procédés de préparation des conjugués d'une manière spécifique comprenant soit la génération de thiols spécifiques d'un anticorps ou d'un agent de protéine de type anticorps, suivie d'une réaction avec des complexes médicament/lieur, soit la génération de thiols spécifiques d'un anticorps ou d'un agent de protéine de type anticorps et la conjugaison d'un ensemble lieur synthétique-médicament avec les thiols simultanément dans une réaction monotope, pour obtenir des conjugués avec plus de 75 %, dans la plupart des cas plus de 80 % de charges utiles liées au niveau des sites de cystéine spécifiques entre des chaînes légères-lourdes de l'anticorps IgG ou de la protéine de type anticorps. L'invention concerne également des procédés d'utilisation du conjugué homogène dans la prophylaxie ou le traitement ciblé du cancer, d'une infection et de troubles immunologiques.